Physician profile
Alan Margolis
NPI 1275739864
$9,355.48
in general payments reported to CMS, 2019-2025
21 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $964 · 2021: $354 · 2022: $868 · 2023: $1,246 · 2024: $2,538 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,280.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $4,973.55 | 2023-2025 | M22, Optilight |
| Allergan, INC. | $1,028.60 | 2019-2022 | |
| Alcon Vision LLC | $619.08 | 2020-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $502.61 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $468.83 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $362.66 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $285.17 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $277.19 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $260.44 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $162.76 | 2024 | Vevye |
| Abbvie INC. | $90.62 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $77.17 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Rayner Intraocular Lenses Limited | $33.33 | 2024 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Oyster Point Pharma, INC. | $31.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.30 | 2019 | |
| Ocular Therapeutix, INC. | $20.50 | 2023 | Dextenza |
| Mallinckrodt Hospital Products INC. | $18.66 | 2023 | Acthar |
| Horizon Therapeutics Plc | $18.55 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $18.35 | 2020 | |
| Pfizer INC. | $16.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.